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1. Introduction 
The prevalence of dementia is expected to increase exponentially worldwide. Global 
estimates of Alzheimer’s disease (AD) - generally considered to be the most common 
subtype of dementia - are expected to increase from the current estimated 25 million to 63 
million in 2030, and by 2050, a staggering 114 million (Wimo et al., 2003). 
Traditional approaches in AD diagnosis (Diagnostic and Statistical Manual- IV (DSM-IV) –
Text Revision (American Psychiatric Association [APA], 2000) and National Institute of 
Neurological Disorders and Stroke- Alzheimer Disease and Related Disorders (NINCDS-
ADRDA) (McKhann et al., 1984) criteria have varying diagnostic accuracy of 65-96% and 
specificity of 23-88% compared to the neuropathologic gold standard (Kazee et al., 1993; Lim 
et al., 1999; Petrovich et al., 2001; Varma et al., 1999). Studies have shown that the hallmark 
histopathological changes of AD (ǃ-amyloid plaques and neurofibrillary tangles) precede 
the clinical onset of disease by as long as 20-30 years (Price & Morris, 1999). This translates 
clinically to functional and structural brain damage where these pathologic changes may 
occur prior to apparent clinical manifestations of cognitive decline by way of standard 
clinical assessments. This has fuelled an increasing shift of diagnostic focus to the pre-
dementia transitional state between normal aging and early AD, which represents a window 
of opportunity for identifying subjects at a phase when pathogenesis has already begun but 
clinical diagnosis of established dementia is still not achievable. This would logically be the 
stage most amenable to disease-modifying interventions (such as ǃ- and gamma-secretase 
inhibitors, anti-amyloid and anti-neurofibrillary tangle therapies). Diagnostic focus thus has 
shifted towards prodromal stages of Alzheimer’s Disease (AD), such as mild cognitive 
impairment (MCI) (Morris et al., 2001; Peterson, 2004). Clinical criteria alone, which by their 
very nature subjective and entail judgment, are thus inadequate to identify the pre-clinical 
stages of AD and may have contributed to the disappointing results of therapeutic trials in 
MCI (a heterogeneous entity) to date.  This has prompted revisions in the upcoming DSM-V 
criteria due in 2013 (Kupfer & Regier, 2010) which include major and minor neurocognitive 
disorder classification, as well as the proposed revision of NINCDS-ADRDA criteria for AD 
to include prodromal AD and preclinical AD, which characterises earliest stage of AD that 
predate crossing of the dementia threshold of functional disability. In the proposed criterion 
by Dubois et al (Dubois et al., 2007), other than clinical criterion of episodic memory deficit, 
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they have also included in criterion E, dominant genetic mutation within the immediate 
family of amyloid precursor protein (Chromosome 21), presenilin 1 (chromosome 14) and 
presenilin 2 (chromosome 1). In consideration of important genetic factors, the presence of a 
proven autosomal dominant mutation has been taken as evidence to support AD diagnosis 
even when clinical features fall outside typical AD criteria. In the working draft for the 
revised NINCDS-ADRDA research criteria for MCI-AD and preclinical AD, there are also 
considerations given to genetics and its influence on disease progression in these pre-
dementia states.  
The rate and presence of clinical manifestation of AD is postulated to be influenced by the 
complex relationship of age, genetic factors, cognitive reserve, cerebrovascular disease, 
which might affect the neuropathogenic progress of amyloid toxicity and subsequent 
clinical presentation of AD (Jack et al., 2010).   Hence in recent years, there has been 
increasing interest in the role of genomics in understanding AD and disease progression.  
In this chapter, we will review the application of genomic, transcriptomic and other ‘omic’ 
platforms and their role in the development of novel diagnostic strategies for AD diagnosis, 
prediction of disease progression and therapeutic drug responses. We will discuss the 
potential clinical applications, the current limitations, ethical dilemmas and the future 
direction of genomics in AD.  
2. Genetics of AD 
The genetic underpinning of AD is heterogeneous and complex, without a straightforward 
mode of inheritance for the vast majority of cases. The heritability of AD in general is 
estimated to be around 60% (Bergem et al., 1997a, 1997b). 
In general, AD can be divided into 2 forms: early onset AD (EOAD) usually those below 65 
years of age, and patients with the late onset AD (LOAD), above 65 years. EOAD largely 
follows a Mendelian autosomal dominant inheritance but they account for less than 5% of 
all AD. Linkage studies have identified three genes thus far for which multiple mutations 
can lead to the pathology. These genes are the amyloid precursor protein (APP) gene on 
chromosome 21q, the presenilin 1 (PSEN1) gene on 14q, and presenilin 2 (PSEN2) gene on 
1q. These mutations all affect Amyloid Precursor Protein (APP) processing and lead to the 
increased synthesis of Aǃ40 and Aǃ42 (See Figure 1). These peptides aggregate to form 
amyloid plaques. Given their rarity, these three gene mutations contribute minimally to the 
estimated 60% heritability of AD. The importance of these rare mutations lies in the 
identification of pathogenic pathways, specifically those involving the catabolism of APP. 
Hence accumulation of Aǃ40 and Aǃ42 is attributed to increased activity of the ǃ and Ǆ 
secretases in familial cases of AD with APP, PSEN1 and PSEN2 gene mutations. However 
environmental or other non-genetic or epigenetic factors may also affect the activities of the 
secretases. This may account for why some cases of PSEN1 and PSEN2 mutations show 
incomplete penetrance and variable onset of illness (Tanzi et al., 1996, 1999). 
Normal individuals with first-degree relatives affected by AD, especially one parent, are at 4 
to10-fold higher risk of developing LOAD compared to those with no family history. 
However no clear Mendelian pattern of transmission has been identified as yet for LOAD. 
Those subjects with a maternal history of dementia showed reduced cerebral metabolic rate 
of glucose in the same regions as clinically affected AD subjects (posterior cingulate cortex, 
precuneus, parietotemporal and frontal cortices, medial temporal lobes) and these effects 
remained after age, gender and education adjustments were made. This may be suggestive 
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of either chromosome X transmission or inheritance of mitochondrial DNA (mtDNA). This 
is especially pertinent as mtDNA deficits are proposed to be involved in AD (Lin & Beal, 
2006; Mosconi et al.,2007) with further recent evidence for sub-haplotype H5 of mtDNA, 
especially in females, to be a risk factor for late onset AD, independent of APOE status 
(Santoro et al., 2010). 
 
 
Fig. 1. Hypothetical pathophysiological cascade of AD and genetic influences on amyloid 
precursor pathways 
Multiple association studies have showed apolipoprotein e4 (APOE e4) to be a genetic 
susceptibility factor, and another allele e2 to be likely protective. Apolipoprotein has three 
alleles e2, e3, e4 located on chromosome 19. They encode cholesterol transport protein APOE 
which is the primary cholesterol transporter in the brain. APOE proteins play a central role in 
the regulation of cholesterol and triglyceride metabolism. They are also present in amyloid 
plaques. In 25% of LOAD patients, there is at least one affected relative in the family (Ritchie & 
Lovestone., 2002). In Caucasian populations, 3-fold increased risk of developing AD has been 
reported for heterozygous APOE e4 and 8-fold risk in homozygous APOE e4 (Roses, 1996). 
Regional, racial and ethnic differences have been observed in APOE e4 genotype frequency, 
with lower carrier status estimates in Asian, southern European/Mediterranean communities 
compared to North American or North European counterparts (Crean et al., 2011). The 
influence of APOE e4 on AD risk, while applicable between ages 40 and 90 years, diminishes 
after the age of 70, and varies across ethnic groups (Farrer et al., 1997). 
The mechanism for the effects of APOE isoforms on brain damage is unclear although a recent 
study demonstrated APOEe4 to cause mitochondrial respiratory dysfunction in neuronal cells 
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through APOEe4 domain interaction. APOEe4, not APOEe3, causes reduced expression of 
mitochondrial respiratory complexes and perturbed mitochondrial respiratory function in 
neuronal cells; thus suggesting that the structure of APOEe4 could be a potential therapeutic 
target for APOEe4-related neurodegeneration (Chen et al., 2010). Other studies have suggested 
that APOEe4 is a disease modifier exerting its effect on disease risk by influencing age of onset 
rather than disease risk per se (Serretti et al., 2007). In this hypothesis, APOEe4 genotype 
modulates disease risk likely by its effect on earlier amyloid ǃ accumulation. 
While APOEe4 status exerts a modulatory effect on disease trajectory and clinical expression 
of disease, it has not been consistently shown to predict MCI-converters (Jack et al., 1999; 
Killiany et al.,2002; Korf et al.,2004 ; Martins et al, 2006;  Okonkwo et al., 2010; Petersen et al., 
2005; Wang et al., 2011). A recent study showed APOE subjects to have 6 times increased 
risk of MCI conversion to AD (Barabash et al., 2009). The role of APOEe4 genotype in 
cholesterol metabolism and Aǃ clearance and interactions in vascular risk factors is 
becoming increasingly recognized (Martins et al., 2006). Midlife high systolic blood pressure 
has a stronger adverse effect on cognitive function in the presence of APOEe4 genotype 
(Peila et al., 2001). Histopathologic data suggest an association between APOEe4 and small 
vessel arteriolosclerosis and microinfarcts of the deep nuclei (Yip et al., 2005).  
In cognitively normal individuals, APOEe2 carriers have slower rate of hippocampal 
atrophy over 2 years than individuals with e3/3. The e2 carriers also have higher CSF ǃ-
amyloid (Chiang et al., 2010; Morris et al., 2010) and lower phosphorylated-tau (p-tau) 
(Chiang et al., 2010) suggesting less AD pathology. Morris also showed a gene dose effect 
for the APOE genotype, with greater mean cortical binding potential for Pittsburgh 
Compound-B binding increases and greater reductions in CSF Aǃ42 with increased numbers 
of APOE alleles; with no effect on CSF tau or p-tau181 (Morris et al., 2010). These findings are 
also supported by the Alzheimer Disease Neuroimaging Initiative study (Vemuri et al., 
2010). Mosconi et al has also shown that normal APOEe4 carriers with subjective memory 
complaints have decreased cerebral metabolic rates for glucose (CMRglc) on 2-[18F] fluoro-2-
deoxy-D-glucose (FDG)-positron emission tomography (PET) (Mosconi L et al., 2008).  
Apart from its effects on clinical progression in at-risk individuals, there have also been 
studies on APOE polymorphism in Alzheimer’s disease patients and neuropsychiatric 
symptoms. APOEe4 AD subjects have been found to be associated with more depressive 
symptoms and apathy (D’Onofrio et al., 2010; Fritze et al., 2010). However this association 
has been inconsistent (Slifer et al., 2009).  
The relationship of APOE genotype with brain function is complex. The APOEe4 carrier state 
is likely to increase the brain’s vulnerability to late-life pathology or cognitive decline 
(Filippinin et al., 2009). APOE also has been postulated to interact with other factors, such as 
homocysteine (Minagawa et al., 2010), smoking (Rusanen et al., 2010), testosterone (Panizzon 
et al., 2010), and other genetic factors like GAB2 haplotype (Liang et al., 2011) which is possibly 
protective, These allude to potential gene-gene interactions between APOE and other factors 
for clinical AD manifestations. APOE as a genetic risk factor is not fully penetrant, and neither 
necessary nor sufficient for AD development (Ertekin-Taner et al., 2010).  
Genetic risk factors are traditionally studied using linkage analysis followed by positional 
cloning, and association studies.  A major drawback is that these hypothesis-driven studies 
depend on pre-existing knowledge limiting their potential to uncover novel genes and 
pathways. Over the past decade, a high-throughput hypothesis-free approach - genome-
wide association study (GWAS) has taken off. This approach examines genetic variation 
across an entire genome and is designed to identify whether certain genes or their variants 
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are skewed to a particular population of individuals affected with disease when compared 
with a control population. This follows recent advancements in developing microarray 
platforms that allow researchers to survey the human genome for single base pair 
differences - single-nucleotide polymorphisms (SNPs) - across many disease cases and 
unaffected controls. For example, Illumina’s Infinium HD Beadchip Human Omni1-Quad® 
and Human 1MDuo® now have excess of one million markers (www.illumina.com). 
Affymetrix Genome-Wide Human SNP Array 6.0® is a single array that features more than 
1.8 million markers for genetic variation, including more than 900,000 single nucleotide 
polymorphisms (SNPs) (www.affymetrix.com).  
By different gene discovery methods, hundreds of genes have been associated with LOAD 
but most have not been consistently replicated except for APOEe4 (Betram et al., 2008). 
Some of the other susceptibility genes reported include ubiquilin 1 (UBQLN1), a presenilin 
interactor that promotes the accumulation of presenilin 1 protein and regulates its 
endoproteolysis (Betram et al., 2005); insulin degrading enzyme (IDE), which regulates 
Aǃ42 levels in brain neurons and microglial cells (Farris et al., 2003; Prince et al., 2003); 
sortilin-related sorting receptor (SORL1), which appears to play a key role in the differential 
sorting of APP. Under-expression of SORL1 leads to APP release into late endosomal 
pathways and processed by beta-secretase cleavage and yielding Aǃ (Andersen et al., 2007; 
Rogaeva et al., 2007). A recent study has also shown MTHFD1L association with AD, which 
might influence homocysteine-related pathways, thus supporting biological evidence of 
folate-pathway abnormalities as homocysteine has been implicated in AD (Naj et al., 2010). 
There is also some recent evidence supporting the role of intermediate genotypes in 
influencing age-related cognitive decline and neuropathologically-proven AD pathology, 
suggesting divergent pathways to AD (Shulman et al., 2010). 
The association studies results can be accessed openly on the AlzGene database - 
(http://www.alzforum.org/res/com/gen/alzgene) for the most up-to-date information. 
This is a huge and rapidly growing database of genes and proteins that researchers have 
found and made available in an open access platform which summarizes results of case-
control AD studies across different racial populations. In the recent 2 years, results from 
large population GWAS studies showed association with the established APOE locus (most 
significant SNP,rs2075650, P = 1.8 x 10(-157)) as well as observed genome-wide significant 
association with SNPs at two loci not previously associated with the disease: at the CLU 
(also known as APOJ) gene on chromosome 8(rs11136000, P = 1.4 x 10(-9)) and 5' to the 
PICALM gene (rs3851179, P = 1.9 x 10(-8)) (Harold D et al., 2009; Seshadri et al., 2010); 
rs744373 near BIN1 (odds ratio [OR],1.13; 95% confidence interval [CI],1.06-1.21 per copy of 
the minor allele; P = 1.59x10(-11)) and rs597668 near EXOC3L2/BLOC1S3/MARK4 (OR, 
1.18; 95% CI, 1.07-1.29; P = 6.45x10(-9)) in a separate Spanish sample (Seshadri et al., 2010). 
Similar results were replicated in a large European study, which showed CLU, (OR = 0.86, 
95% CI 0.81-0.90, P = 7.5 x 10(-9) for combined data) and the other within CR1, encoding the 
complement component (3b/4b) receptor 1, on chromosome 1 (rs6656401, OR = 1.21, 95% CI 
1.14-1.29, P = 3.7 x 10(-9) for combined data). Previous biological studies have supported 
CLU and CR1’s role in Abeta peptide clearance (Lambert et al., 2009) and their interactions 
with APOE genotype (Gyungah et al., 2010). Another gene locus of interest is TOMM40, 
gene in LD with APOE, which may contribute to APOE correlations with AD risk and age of 
onset (Roses et al., 2009) (See Table 1). Although genetic associations have been 
demonstrated, such as CLU and PICALM, in a study by Seshadri, these loci did not improve 
AD risk prediction (Seshadri et al., 2010). 
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Year  
published 
 
Authorship 
 
Source Initial Number 
of cases/ 
controls 
 
Reported Genes 
2011 Lee  
(Lee et al., 2011) 
US 549/544 CUGBP2 (APOE4 
homozygous), 
HPCAL1, PCDH21, 
LRITI, RGR, CLU, 
PICALM, BIN1 
2010 Carrasquillo  
(Carrasquillo et 
al., 2010) 
US 1829/2576 CLU, CRI, PICALM 
2010 Seshadri  
(Seshadri et al., 
2010) 
US 10968/14642 APOE 
2010 Naj  
(Naj et al., 2010)  
US 931/1104 APOE,TOMM40, 
MTHFD1L, PVRL2 
2009 Heinzen  
(Heinzen et al., 
2010) 
US 331/368 TOMM40, APOE, 
RFC3, TTLL7, 
PAX2, SASHI 
2009 Harold  
(Harold et al., 
2009) 
US/ Europe 3941/7848 APOE, TOMM40, 
CLU, PICALM 
2009 Lambert  
(Lambert et al., 
2009) 
Europe 2032/528 APOE, CR1, CLU 
2009 Carrasquillo  
(Carrasquillo et 
al., 2009) 
US 844/1255 PCDH11X 
2009 Poduslo  
(Poduslo et al., 
2009)* 
US 140(family) & 
199 
(unrelated)/85 
(unrelated 
controls) 
TRPC4AP 
2009 Feulner  
(Feulner et al., 
2009) 
Germany 491/479 TOMM40, APOE 
2009 Beecham  
(Beecham et al., 
2009) 
US 492/496 FAM113B, ZNF224 
2008 Bertram  
(Bertram et al., 
2005) # 
US 941/404 CD33 
2008 Abraham  
(Abraham et al., 
2008) 
UK 1082/1239 PVRL2, TOMM40, 
APOE 
www.intechopen.com
 
Alzheimer’s Disease Genomics and Clinical Applications 
 
27 
Year  
published 
 
Authorship 
 
Source Initial Number 
of cases/ 
controls 
 
Reported Genes 
2008 Li  
(Li et al., 2008) 
Canada/ UK 753/736 APOE, APOC1 
2008 Webster  
(Webster et al., 
2008)  
US 664/422 APOE 
2007 Reiman  
(Reiman et al., 
2007)  
US/ Netherlands 415/260 GAB2 
2007 Coon  
(Coon et al., 
2007) 
US/Netherlands 664/422 APOE 
2007 Grupe  
(Grupe et al., 
2007) 
UK/US 1428/1666 GALP, THNK1, 
chr14q32.13, PCK1, 
LMNA, PGBD1, 
LOC651924, 
chr7p152, THEMS, 
MYH13, CTSS, 
UBD, BCR, AGC1, 
TRAK2, EBF3 
All case control studies except # (family-based) and * (family-based and case control) 
Table 1. Selected recent GWAS studies and genes reported Adapted from the Alzheimer 
Disease database of the National Human Genome Research Institute, NIH. 
(www.genome.gov) 
Recent findings in an adequately powered study failed to detect evidence for association 
between common variants in BIN1, CLU, CR1 and PICALM with CSF Aǃ42 and ptau-42; 
This original hypothesis that gene variants might affect risk via an additive effect has yet to 
be substantiated. The authors concluded that the negative findings might suggest that the 
rare, rather than common, variations influence the CSF biomarkers and that other complex, 
non-additive genetic mechanisms, such as gene-gene and gene-environment interactions 
play major roles (Kauwe et al., 2011).  
Copy number variations (CNV) which include segments of DNA ranging from 1kb – several 
Mb have been postulated to show differences in regional copy number when comparing 2 or 
more genomes although a recent study did not show any new SNPs of genome-wide 
significance (Heinzen et al., 2010).  
3. From genomes to transcriptomes  
Beyond DNA, other sources of variability are related to transcriptional, translational and 
post-translational modifications all the way to environmental factors. Hence from the study 
of the collective genotypes of an individual, one logically moves to the study of the genome-
wide gene expression products, also called ‘transcriptomics’. Here we are not looking only 
at which genes are present in an individual but which genes are actually transcribed into 
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messenger RNA (mRNA). While the genome is fixed for an individual, the transcriptome, 
i.e. the set of mRNAs produced in an individual corresponding to its genome, varies 
between different tissue types, across the life cycle of the cells, the life cycle of the organism, 
changes in the internal or external milieu, epigenetic and other factors. Hence the 
transcriptome reflects the genes that are being actively expressed in the tissue or cell type 
under study at one point in time. Transcriptomics usually employs high-throughput 
techniques based on oligonucleotide  microarray technology platforms.  For example 
Illumina’s Whole-genome expression HT-12 v4.0 beadchip® targets more than 28,000 
coding transcripts with well-established annotations derived from the RefSeq and the 
UniGene databases (www.illumina.com). Another one commonly used is the Affymetrix 
GeneChip Human Genome U133 Plus 2.0 Array® (www.affymetrix.com).  
An example of a transcriptomic study would be comparing the mRNA levels between samples 
obtained from AD patients versus healthy controls. Significant differences in mRNA levels 
would imply that the genes are expressed to different degrees and this may lead downstream 
to different levels of protein translation and several steps further into disease phenotypes. 
The first area of interest is whether the findings from transcriptomics correspond to those 
obtained from classical genetics or GWAS, for example, with reference to APOEe4, APP, 
PSEN1, PSEN2. A seminal study by Liang and coworkers demonstrated how different 
regions of the brain have different expression profiles by analyzing six anatomically discrete 
postmortem brain regions – entorhinal cortex, hippocampus, middle temporal, posterior 
cingulate, superior frontal gyri and primary visual cortex, comparing AD patients with 
normal controls (Liang et al., 2008). They showed a correlation between their findings with 
those obtained by other investigators using genotyping and GWAS. They found altered 
expression of factors previously implicated in AD pathogenesis, including APP, PSEN1, 
SORL1, and BACE1. APP gene expression was markedly increased in the hippocampus, 
medial temporal, posterior cingulated gyri and visual cortex in AD subjects whereas BACE1 
displayed decreased expression in entorhinal cortex, medial temporal gyrus and 
hippocampus. They also found decreased expression for microtubule associated protein tau 
(MAPT) and decreased expression for alpha and beta tubulin proteins (which form the 
building blocks of microtubules) in entorhinal cortex, hippocampus, medial temporal and 
posterior cingulated gyri. These observations may help in explaining the relationship 
between NFTs and amyloid plaques.  
Other investigators have focused on specific regions of the brain. Studying specifically the 
neocortex, Tan and co-workers found evidence of synaptic dysfunction, disturbed 
neurotransmission and activation of neuroinflammation in AD subjects when compared to 
normal controls (Tan et al., 2010). In a case control study of 22 AD subjects and 9 normal 
controls, Blalock examined gene expression patterns in the hippocampus and found up-
regulation of many transcription factor/signaling genes regulating proliferation and 
differentiation, including tumor suppressors, oligodendrocyte growth factors and protein 
kinase A modulators. In addition, there was up-regulation of adhesion, apopotosis, lipid 
metabolism and initial inflammation processes. Protein folding/metabolism and signaling 
pathways were conversely down-regulated (Blalock et al., 2004).  
To overcome the limitations of gene expression profiling due to the substantial intra-
individual regional brain differences and inter-individual heterogeneity, Dunckley 
compared the gene expression profiles of three groups:  (1) neurofibrillary tangle-bearing 
entorhinal cortex neurons from 19 AD patients with (2) adjacent non-tangle bearing neurons 
from the same patients and (3) histologically normal non-AD controls. 225 genes showed 
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progressively increased and decreased expression in the 3 groups. Not unexpectedly many 
of the genes coded for proteins implicated in NFT formation, especially in the early stages of 
formation (Dunckley et al., 2006). 
Another approach employed was to correlate gene expression profiles according to   
histological staging of AD. Bossers and co-workers correlated changes in gene expression to 
the progression of AD in prefrontal cortex brain samples from 49 patients using the standard 
Braak histopathological system of staging post mortem brain tissue samples for 
neurofibrillary changes as an objective indicator of AD progression et al (Bossers et al., 
2010). The Braak stages range from I to VI, with an additional Stage 0 referring to the 
absence of neurofibrillary change. They found 2 distinct patterns of tightly co-regulated 
groups of genes. Firstly, there was an increase in the expression of genes involved in 
synaptic activity and changes in the plasticity during the early Braak stages. However, the 
expression of this same group of genes was reduced in the later Braak stages. There was also 
an increase in intracellular amyloid beta staining from Braak Stages I to II but a decrease in 
Braak stages IV to VI. For the genes up-regulated in the early Braak stages, there were 
several genes involved in amyloid precursor protein processing and beta amyloid clearance. 
The authors thus suggested that the temporally correlated upregulation of synaptic genes 
activity represents a compensatory mechanism against increased soluble amyloid beta (Aǃ) 
levels, and that this could possibly be a good place to identify new targets of anti-dementia 
drug development. 
The most important factor in transcriptomics and also the downstream ‘omic’s is the tissue 
of study. Human brain tissue for analysis can only be obtained post-mortem and sampled 
only once. This tissue usually reflects a late-stage disease unless an AD subject had died of 
another cause early in the disease. Moreover RNA quality and quantity are highly 
dependent on the pre and post-mortem conditions and around tissue harvesting. The other 
major concern is the region of sampling as the brain is anatomically and histologically 
extremely heterogeneous. The choice of which anatomical brain region to study, gray versus 
white matter, neocortex versus archicortex greatly influences the results. Therefore much 
transcriptomic research endeavor has been directed towards blood. Blood is readily 
available and can be re-sampled repeatedly, allowing for longitudinal assessment of gene 
dysregulation at different disease stages. This could assist in making diagnoses, tracking the 
disease course and evaluation of disease altering interventions.  Blood derived nuclear 
material is by no means a direct proxy for neuronal tissue, but it may reflect certain aspects 
of the CNS milieu, or systemic manifestations of the underlying disease. More importantly 
they can serve as peripheral biomarkers of disease. Gene expression profiling of peripheral 
blood has been shown to provide distinctive profiles for a few neurological conditions (Tang 
Y et al., 2001, 2003). Similarly psychiatric disorders were also found to have unique gene 
expression signatures (Tsuang et al. , 2005). Nevertheless extrapolating blood-derived data 
to the brain tissue still poses major challenges. In transcriptomic studies, due to the large 
numbers of genes in the genome that are differentially expressed, the up or down-regulated 
genes may be implicated as potentially casually related to AD pathology, downstream 
consequences of the disorder, reflect compensatory mechanisms, or found simply by chance 
alone. This type-one error is likely by virtue of the large number of genes sampled. 
Probably the first major publication on the blood-derived gene expression for AD was by 
Maes and his co-workers who studied the expression profiling of blood mononuclear cells of 
AD subjects versus normal controls (Maes et al., 2008). They reported that 28% of the 
upregulated genes and 16% of the downregulated genes have been previously reported to 
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exhibit similar expression patterns in AD brain, whereas only 4% of affected genes were 
divergent in terms of expression between blood and brain. This comparison is important as 
it suggested the systemic nature of altered gene expression in AD and demonstrated the 
usefulness of blood as putative probes of CNS dysfunction.   After comparing over 6000 
genes, they found a significant decline in gene expression in the pathways of cytoskeletal 
maintenance, cellular trafficking, cellular stress response, redox homeostasis, transcription 
and DNA repair (Maes et al., 2007). Moreover they reported that the majority of upregulated 
transcripts function in apoptotic and inflammatory pathways, including those involved in 
TNF alpha signaling and caspase pathways.  Using whole blood samples of AD patients 
versus normal controls, Grunblatt et al found that five out of 33 genes were differentially 
expressed and showed significant correlation to the severity of AD (Grunblatt et al., 2009). 
More recently, Booij et al developed a 96-gene microarray using blood samples from a large 
clinical cohort of 203 probable AD patients and 209 cognitively healthy age-matched 
controls and has patented it for commercial use, specifically for detection of early AD - 
ADtect® by DiaGenic ASA based in Oslo, Norway (www.diagenic.com). A disease 
classification algorithm was developed on samples from 208 individuals (AD = 103; controls 
= 105) and was validated in two steps using an independent initial test set (n = 74; AD= 32; 
controls = 42) and another second test set (n = 130; AD= 68; controls = 62). In the initial 
analysis, diagnostic accuracy was 71.6±10.3%, with sensitivity 71.9±15.6% and specificity 
71.4±13.7%. (Booij et al., 2010; Rye et al., 2010).  
In summary, the transcriptomic studies regardless of tissue of origin, has yielded a large 
number of genes and putative mechanisms and pathways, including the ‘usual suspects’ as 
outlined previously. However no simple conclusions can be arrived at from this approach at 
this time. The fragmented and sometime incongruous lists of pathways and mechanisms 
attest to the heterogeneous nature of AD and await further replication and confirmation. 
Furthermore, most of the transcriptomic studies have focused on neuroanatomical and 
histological stages of AD. The current lack of longitudinal data and translation of genetic 
correlations to neuroimaging changes limits its role to a primarily investigative exploration 
of AD pathogenesis.  
4. The other ‘Omics’ 
Looking further downstream, although microarray studies can reveal the relative amounts 
of different mRNAs in the cell, levels of mRNA per se are not directly proportional to the 
level of the proteins they code for nor the eventual protein configuration. Each protein first 
arises as an unfolded polypeptide when translated from mRNA to a linear chain of amino 
acids. The amino acids interact with each other to produce complex three dimensional 
structures, and their folding configuration is essential to protein function. The complete 
protein complement of a cell, including protein structures is now referred to as the 
proteome. Proteomics refer to the study of the plethora of proteins across the whole 
organism and is one step closer to the phenotype (Simonsen et al., 2007). 
Like transcriptomics, proteomics is usually applied to compare the differences in 
abundances of proteins between diseased and normal subjects. The technologies involved in 
proteomics are very complex and beyond the scope of this review. Proteomic discoveries are 
limited thus far but more would be expected in the next few years. The proteomic 
techniques have been applied to discover biomarkers for AD in CSF but the results thus far 
are inconclusive. Simonsen et al found a 17-protein biomarker using cerebrospinal fluid 
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samples to predict the progression from mild cognitive impairment to AD in a sample of 113 
patients (Papassotiropoulos et al., 2006).  German et al. reported finding three discriminating 
peaks in common but these peaks still await identification of the proteins and peptides 
(German et al. , 2007). Portelius proposed that targeted proteomics on Aǃ may provide 
novel assays for biomarkers for AD (Portelius et al., 2008). Investigating the proteome of the 
hippocampus, Sultana and her co-workers employed 2-dimensional gel electrophoresis and 
mass spectrometry to determine the changes in protein levels in AD and controls (Sultana et 
al. , 2007). They identified 18 proteins with altered protein levels and which were involved 
in regulating different cellular functions. This study gives preliminary data on the levels of 
key proteins in the AD brain. A comprehensive review of the state of the art of proteomics in 
AD has been published by Zellner (Zellner et al., 2009). 
As a corollary to proteomics, metabolomics is the global approach to understanding 
regulation of metabolic pathways and metabolic networks (Kaddurah-Daouk et al., 2009). 
This involves the study of the complete set of small-molecule metabolite, such as metabolic 
intermediates, hormones, other signaling molecules, and secondary metabolites. The 
metabolome is dynamic, changing from minute to minute and provides a snapshot of the 
physiology of the cell. It is not currently possible to analyze the entire range of metabolites 
by a single analytical method. Kaddurah-Daouk compared samples from post-mortem 
ventricular cerebrospinal fluid of 15 AD with 15 non-demented subjects and identified 
alterations in tyrosine, tryptophan, purine and tocopherol pathways in patients in AD 
(Kaddurah-Daouk et al., 2010). She also noted a reduction in norepinephrine and its related 
metabolites. Barba and co-authors published a useful review of the rationale and 
methodology of metabolomics in AD (Barba et al., 2008). The applications for metabolomic 
analysis in AD is still in infancy but will emerge as a powerful tool in CNS research, as it 
complements data derived from the other ‘omics’ to assist in providing a systems approach 
to the study of human health and disease.  
Epigenetics refer to molecular and cellular effects on gene expression without a change in 
the DNA sequence. These effects include DNA methylation, histone modification and RNA 
mediated gene silencing. Epigenomics is the genomic-wide study of epigenetic effects. 
While all nucleated cells in an individual contain the same genome, they contain very 
different epigenomes depending on tissue type, developmental stage, environmental 
influences and other parameters (Murrell et al., 2005; Stamatoyannopoulos et al., 2008). 
These affect the individual presently and can be transmitted into the next generation 
without a change in the underlying DNA code. Epigenetic contribution is vital to achieve 
either stable expression or repression of genes at various stages of development (Chouliaras 
et al., 2010; Wu et al., 2008). 
DNA methylation is currently one of the most studied modification and is accomplished 
through DNA methyltransferases, which transfer a methyl group to the cystosine of CpG 
dinucleotides. The cystosine DNA-methyltransferase genes play a critical role in the 
establishment of transcriptionally repressive complexes.  It plays an important role in gene 
silencing and regulating gene expression. Epigenetic mechanisms are dynamic and 
changeable even in fully differentiated brain cells. Among the various epigenetic 
mechanisms, histone acetylation and phosphorylation can open up the chromatin structure 
and may favor gene transcription. DNA methylation is more often associated with increased 
condensation of chromatin and gene silencing. However the effects of such epigenetic 
mechanisms may be gene dependent (Gräff et al., 2009).  
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In investigating LOAD, Wang and his co-workers proposed that epigenetic contribution in 
the development of the disease could be inferred from several observations (Wang et al., 
2008). These include the fact that sporadic cases of AD dominate over familial ones; a 
concordance rate of monozygotic twins well below 100%; differential susceptibility and 
course of illness in males and females; parent-of-origin effect; and relatively late age of 
disease onset. In AD brain they found aberrant histone modifications and abnormal folate 
(Coppede et al., 2010) and homocysteine levels, which were indicative of abnormal 
methylation homeostasis and epigenetic dysregulation. Even for EOAD, the difference in 
penetrance and expressivity can be attributed in part to epigenetic phenomenon. They 
argued that the epigenome is particularly susceptible to dysregulation during embryonic 
and neonatal development, puberty and old age. When studying DNA methylation patterns 
on a series of candidate genes in postmortem brains and lymphocytes from LOAD patients 
versus healthy controls, they further found that the largest inter-individual variance in DNA 
was observed in PSEN1 and APOE promoters and postulated that hypomethylation of 
PSEN1 promoter could induce an overexpression of PSEN1. They also found that there were 
substantial differences in the epigenetic profiles between old monozygotic twins that can be 
attributed to one’s environmental exposure, lifestyle, diet, or merely stochastic fluctuations. 
They reported that the strongest age-effects were detected in NCSTN gene that codes for 
nicastrin, which participates in the regulation of gamma-secretase cleavage of the APP. 
Hence they hypothesized that neuronal tissue in the AD brain may be prone to collecting 
epimutations with time due to their post-mitotic state, as opposed to cells which are 
constantly being renewed. 
Mastroeni and co-workers studied the immunoreactivity for two markers of DNA 
methylation and eight methylation maintenance factors in the entorhinal cortex layer II, a 
region that has been implicated in the histopathology of AD (Mastroeni et al., 2010). They 
demonstrated neuronal immunoreactivity for all 10 of the epigenetic markers and factors, 
with  significant decrements in AD cases. These decrements were particularly marked in 
certain neurofibrillary tangle-bearing neurons. In addition, two of the DNA methylation 
maintenance factors were decreased in AD subjects. Hence they concluded that epigenetic 
dysfunction occurred in AD-vulnerable neurons. 
5. Clinical applications of the ‘Omics’ 
The involvement of genetic approaches in the diagnosis, risk prediction of AD in the 
established and at-risk (pre-dementia) states includes its use in combination with clinical 
parameters and biomarker supplementation (Crunchaga et al., 2010). Another potential 
application is based on quantitative endophenotype data to provide greater statistical power 
for subject inclusion in clinical therapeutic trials via genetics-imaging approaches. This later 
approach has been adopted by the US NIH Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) and European Union FP6-funded AddNeuroMed study (Mueller SG, 2005) 
(Lovestone et al., 2007; Shen et al., 2010). Specific loci such as PICALM has been shown to be 
the most significant gene associated with entorhinal cortical thickness (Biffi et al., 2010). 
Over-representation of rs10845840, located in the GRIN2B gene, which encodes the N-
methyl-d-aspartate (NMDA) glutamate receptor NR2B subunit has been found to be 
associated with lower temporal lobe volume (Stein et al., 2010). Distinct variants of SORL1 
has been demonstrated to be associated with cerebrovascular and neurodegenerative 
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changes related to AD (Cuenco et al., 2008); and APOE and TOMM40 with multiple brain 
regions (Shen et al., 2010). 
APOE genotype has also been shown to be associated with increased blood oxygen level-
dependent (BOLD) signal on functional magnetic resonance imaging (fMRI) in the occipital 
and perisylvian cortices bilaterally. More work needs to be done looking at the paradigm, 
family history and age to further interpret the BOLD differences between e4 carriers and 
non-carrier states, which might provide information on default modal networks involved in 
AD (Ringman et al., 1993;  Trachtenberg et al., 2010).  
The effects of genetics on therapeutic response to AD are potentially via the use of genomic 
information for the selection of at-risk groups as well as genetic influences on treatment 
efficacy and complications in the burgeoning field of pharmacogenomics. In particular, it 
has been shown that those with APOEe4 genotype do better  on donepezil during the initial 
1-year period (Petersen et al., 2005); but fair less well during the phase II trial of 
rosiglitazone (Risner et al., 2006) (peroxisome proliferator-activated receptor Ǆ agonist), and 
the higher incidence of reversible vasogenic edema  when treated with bapineuzumab 
(Kaufer et al., 2009). There is also some epidemiological rationale for the use of 
curcuminoids in AD which may be explained by the enhanced phagocytosis of Aǃ via 
upregulation of transcription of specific genes (MGAT3) and translation of TLR2-4 (Fiala et 
al., 2007).  
The main utility of GWAS currently lies in its potential in their hypothesis-generating nature 
to understand the pathophysiological pathways and ability to correct for population 
stratifications using principal component adjustments in homogenous populations, 
especially when low levels of increased risks are involved. Although there are current 
studies proposing the use of a 96-gene expression array (using blood RNA) for early AD 
diagnosis (Booij et al., 2010; Rye et al., 2010), the clinical accuracy is modest, estimated at 
80%, and comparable to current clinical assessment methods.  
While the idea of a diagnostic gene test kit to diagnose early AD is appealing, we have to be 
mindful of the diagnosis in asymptomatic at-risk individuals, given the current lack of 
concrete benefit of disease-modifying treatments and the modest benefits conferred by 
cognitive enhancers (Caselli et al., 2010). There are also concerns about the amount of age-
related AD-like pathology one would accept as normal before offering potentially useful but 
yet unproven treatment strategies, which might promote ’cognitive hypochondriasis’. An 
example would be the controversial “Alzheimer’s Mirror” genetic test developed by Smart 
Genetics, a Philadelphia company, which developed test kit for APOE variants and ceased 
operations 8 months after initial launch (Erika et al., 2008). 
6. Limitations of methods and works in progress  
Foremost is the absence of a time axis as most studies are based on a snapshot. While this is 
not vital in DNA studies, it is very relevant for transcriptomic, proteomic, metabolomics, 
epigenomic and most imaging studies. As mentioned previously, human tissue derived 
from postmortem specimens largely reflects advanced or terminal stage of disease and the 
quality of the tissue is dependent on the agonal and postmortem conditions. CSF and blood 
can only be a proxy of the intracerebral condition. However sampling CSF and blood allows 
longitudinal study and repeated sampling. Another major issue is ‘spatial’. The brain is not 
a homogenous tissue and regional differences are significant. Hence whole brain sampling 
will not reflect regional variation and significant differences may be ‘lost in translation’. This 
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has been somewhat mitigated by microdissection and single-cell sampling. However 
looking at individual cells or cell types ignores the complex and interconnected nature of 
brain tissue and function. Other researchers have focused on studying transgenic mice or 
cell lines as informative proxies. Therefore there is no single best approach, and a 
combination of approaches, analyzed collectively and stratified according to ethnic 
variability will likely yield the most meaningful results. 
There is currently strong interests in genomics and the various groups, for example the 
Dominantly Inherited Alzheimer Network (DIAN) (http://www.dian-info.org), which is 
presently enrolling study participants who are biological adult children of a parent with a 
mutated gene known to cause dominantly inherited Alzheimer’s disease. Others include the 
ADNI Genetics Core and OPAL (Opportunity for Prevention of Alzheimer’s) 
(http://www.opalstudy.org) which are recruiting normal subjects, defined by 
neuropsychological testing, between 60 and 87 years and genotyped for APOE status and 
TOMM40 '523 polymorphisms. Then, based on their age and TOMM40 status, they will 
either fall into the high-risk or low-risk category for developing Alzheimer's in the next five 
years with potential therapeutic drug administered.  
7. Conclusions 
In recent years, there has been much progress made in the recent high throughput 
technologies that has led to a better understanding of AD. Mutations in the genes APP, 
PSEN1 and PSEN2 in autosomal dominant inheritance patterns in EOAD are fairly well 
established. For LOAD, with an estimated heritability of around 60%, the principal 
susceptibility gene remains APOEe4 with several others, which play much lesser roles. 
There is evidence for APOE gene profiling for prospective epidemiological study research 
and pharmacogenetics in identifying high-risk individuals as well as the potential response 
to current therapeutic agent with calls for APOEe4 genotype to be a covariate for AD clinical 
trials in view of its modulatory effect on disease progression (Farlow et al., 2010). Broader 
genetic profiling via GWAS approach very recently has identified susceptibility at-risk 
genes. However, the individual effects of these identified gene loci are individually small 
but may identify genes for further functional investigation.  
The endeavors in gene expression, proteomics and metabolomics, all downstream from 
genomics, are relatively early in their development and the results are very preliminary. This 
is in part due to the limitations of the technology and the tremendous challenges posed by 
analyzing huge datasets with current bioinformatic and computational biology capabilities. 
Epigenomics is another burgeoning area of tremendous promise. It runs parallel to genomics 
for it affects gene transcription and translation in ways beyond the actual DNA code. 
Extraneous and environmental factors can affect the epigenetic modifications. While DNA 
methylation and histone modifications are better understood, a far larger scope of epigenomics 
lies in the near horizon. Integrative approaches to complex multi-gene interaction and 
epigenetic effects using sophisticated algorithms have begun and would likely yield more 
robust results. However, the current state of genomics in diagnostics, risk prediction and 
potential inclusion in therapeutic trials still favor the established APOE given the 
demonstration of modulatory effect even in the preclinical stages of disease. The unfulfilled 
potential of these other high throughput platforms lie mainly in the lack of longitudinal data 
reflecting change as well as correlations with a more 'measurable' structural and functional 
brain measure, limiting its current role to a purely investigative one. 
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Moving forward, large scale collaborative efforts across high throughput technologies are 
required to understand the role of amyloid, lipid homeostasis and chronic inflammation in 
AD pathogenesis as well as therapeutic interventions directed at these various proposed 
pathways. 
There is a need for diagnostic-therapeutic co-development approach especially in complex 
disorders such as AD to create diagnostic and prognostic algorithms via a multi-modal 
approach together with clinical and biomarker supplementation. This will lead to eventually 
fulfill the role of genomics in predictive, preventive and personalized medicine. In 
anticipation of this, a recent GRIPS (Genetic Risk Prediction Studies) Statement 
recommendation has also been published to enhance transparency of study reporting, and 
thereby improve the synthesis and application of multiple studies which may differ in terms 
of study design, protocol and analytical methods (Janssens et al., 2011).  
8. References 
Abraham R, Moskvina V, Sims R, et al. (2008) A genome-wide association study for late-
onset Alzheimer’s disease using DNA pooling. BMC Med Genomics; 1:44. 
American Psychiatric Association. (2000) Diagnostic and statistical manual of mental 
disorders (IV-TR) 4th edn – text revision. Washington, DC. 
Andersen OM, Willnow TE, Graff-Radford N, et al. (2007) The neuronal sortilin-related 
receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. Feb; 39 
(2): 168-77. 
Barabash A et al. Neurobiology Aging (2009); 30:1254-64. APOE, ACT and CHRNA7 genes 
in the conversion from amnestic MCI to AD. Neurobiology Aging; 30:1254-64. 
Barba I, Fernandez-Montesinos R, Garcia-Dorado D, et al. (2008) Alzheimer’s Disease 
beyond the genomic era:nuclear magnetic resonance (NMR) spectroscopy-based 
metabolomics. J cell Mol Med 12(5A): 1477-85. 
Beach T, Leung D, Bryden L, et al. (2008) Sorl1 as an Alzheimer's disease predisposition 
gene? Neurodegener Dis., 5(2):60-4. 
Beecham GW, Martin ER, Li YJ, et al. (2009) Genome-wide association study implicates a 
chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet, 84:35-
43. 
Bergem AL, Engedal K, Kringlen E. (1997) The role of heredity in late-onset Alzheimer 
disease and vascular dementia. A twin study. Arch Gen Psychiatry, 54: 264-70. 
Bergem AL, Lannfelt L. (1997) Apolipoprotein E type epsilon4 allele, heritability and age at 
onset in twins with Alzheimer disease and vascular dementia. Clin Genet, Nov; 
52(5): 408-13. 
Bertram L, Hilunen M, Parkinson M, et al. (2005) Family-based association between 
Alzheimer’s disease and variants in UBQLN1. N Engl J Med 352: 884-894. 
Betram L, Lange C, Mullin K, et al. (2008) Genome-wide association analysis revelas 
putative Alzheimer’s disease susceptibility loci in addition to APOE. Am J Hum 
Genet, 83:623-32. 
Biffi A, Anderson CD, Desikan RS et al. (2010) Genetic variation and Neuroimaging 
Measures in Alzheimer Disease. Arch Neurol, 67(6):677-85. 
www.intechopen.com
 The Clinical Spectrum of Alzheimer’s Disease  
– The Charge Toward Comprehensive Diagnostic and Therapeutic Strategies 
 
36
Blalock EM, Geddes JW, Chen KC, et al. (2004) Incipient Alzheimer’s disease: Microarray 
correlation analyses reveal major transcriptional and tumor suppressor responses. 
PNAS, 101(7):2173-2178. 
Booij BB, Lindahl T, Wetterberg P, et al. (2011) A gene expression pattern in blood for the 
early detection of Alzheimer’s Disease 23:1-11. J Alzheimers Dis. Jan 1;23(1):109-19. 
Bossers K, Wirz KTS, Meerhoff GF, et al. (2010) Concerted Changes in Transcripts in the 
Prefrontal Cortex Precede Neuropathology in Alzheimer’s Disease. Brain 133: 3699-
3723. 
Carrasquillo MM, Belbin O, Hunter TA, et al. (2010) Replication of CLU, CR1, and PICALM 
associations with alzheimer disease.  Arch Neurol. Aug; 67(8):961-4. Epub Jun 14. 
Carrasquillo MM, Zou F, Pankratz VS, et al. (2009) Genetic variation in PCDH11X is 
associated with susceptibility to late-onset Alzheimer disease. Nat Gent, 41:192-8. 
Caselli RC, Dueck AC. (2010) APOE ε 2 and presymptomatic stage Alzheimer disease. 
Neurology, 75:1952-3. 
Chen HK, Ji ZS, Dodson SE, et al (2011) Apolipoprotein E4 Domain Interaction mediates 
detrimental effects on Mitochondria and is a potential Therapeutic target for 
Alzheimer’s disease. J Biol Chem. Feb 18; 286(7):5215-21.  
Chiang GC, Insel PS, Tosun D, et al. (2010) Hippocampal atrophy rates and CSF biomarkers 
in elderly APOE2 normal subjcts. Neurology; 75:1976-81. 
Chouliaras L, Sierksma ASR, Kenis G et al. (2010) Gene-Environment Interaction Research 
and Transgenic Mouse Modles of Alzheimer’s disease. Int J Alz Dis. Oct 5.  
Coon KD, Myers AJ, Craig DW, Webster JA et al. (2007) A high-density whole-genome 
association study reveals that APOE is the major susceptibility gene for sporadic 
late-onset Alzheimer’s disease. J Clin Psychiatry; 68:613-18. 
Coppede F. (2010) One-Carbon Metabolism and Alzheimer’s disease: Focus on Epigenetics. 
Curr Genomics; 11:246-60. 
Crean S, Ward A, Mercaldi CJ, et al. (2011) Apolipoprotein E ε4 prevalence in Alzheimer’s 
disease patients varies across global populations: A Systematic Literative Review 
and Meta-Analysis. Dement Geriatr Cogn Disord; 31;20-30. 
Crunchaga C, Kauwe JSK, Mayo, et al. (2010) SNPs associated with cerebrospinal fluid 
phospho-tau levels influence rate of decline in Alzheimer’s disease. PLOS; 6(9): 
e1001101. 
Cuenco KT, Lunetta KL, Clinton T, et al. (2008) Association of distinct variants in SORL1 
with cerebrovascular and neurodegenerative changes related to Alzheimer disease. 
Arch Neurol; 65:1640-8. 
D’Onofrio G, Panza F, Seripa D, et al. (2010) The APOE polymorphism in Alzheimer’s 
disease patients with neuropsychiatric symptoms and syndromes. Int J Geriatr 
Psychiatry. Oct 29. 
Dubois B, Feldman HH, Jacova C, et al. (2007) Research criteria for diagnosis of Alzheimer’s 
disease: revising the NINCDS-ADRDA criteria. Lancet Neurol; 6:734-46.  
Dunckley T, Beach TG, Ramsey KE, et al. (2006) Gene expression correlates of neurofibrillary 
tangles in AD. Neurobiol Aging. 27(10):1359-1371. 
Ertekin-Taner N. (2010) Genetics of Alzheimer’s disease in the pre- and post-GWAS era. Alz 
Res Therapy, 2:3. 
www.intechopen.com
 
Alzheimer’s Disease Genomics and Clinical Applications 
 
37 
Farlow MR. (2010) Should the ApoE genotype be a covariate for clinical trials in Alzheimer 
disease? Alz Res Ther; 2:15. 
Farrer LA, Cupples LA, Haines JL, et al. (1997) Effects of age, sex, and ethnicity on the 
association between apolipoprotein E genotype and Alzheimer disease. A meta-
analysis. JAMA; 278: 1349-1356. 
Farris W, Mansourian S, Chang Y, et al. (2003) Insulin-degrading enzyme regulates the 
levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein 
intracellular domain in vivo. Proc Natl Acad Sci USA 100:  4162-67. 
Feulner TM, Laws SM, Friedrich P, et al. (2009) Examination of the current top candidate 
genes for AD in a genome-wide association study. Mol Psychiatry, Jan 6. 
Fiala M, Liu PT, Espinosa-Jeffrey A, et al. (2007) Innate immunity and transcription of 
MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by 
bisdemethoxycurcumin. Proc Natl Acad Sci U S A. Jul 31;104(31):12849-54. 
Filippinin N, Ebmeir KP, Macintosh BJ, et al. (2011) Differential effects of the APOE 
genotype on brain function across lifespan. Neuroimage; 54:602-610. 
Fritze F, Ehrt U, Sonnesyn H, et al. (2010) Depression in mild dementia: associations with 
diagnosis, APOE genotype and clinical features. Int J Geriatr Psychiatry. Oct 28. 
German DC, Gurnani P, Nandi A, et al. (2007) Serum biomarkers for Alzheimer's disease: 
proteomic discovery. Biomed Pharmacother. Aug; 61(7): 383-9.  
Gräff J, Mansuy IM. (2009) Epigenetic dysregulation in cognitive disorders. European Journal 
of Neuroscience pp. 1-8. 
Grunblatt E, Bartl J, Zehetmayer, et al. (2009) Gene expression as peripheral biomarkers for 
sporadic Alzheimer’s Disease. J Alzheimer’s Disease, 16:627-634. 
Grupe A, Abraham , Li Y, et al. (2007) Evidence for novel susceptibility genes for late-onset 
Alzheimer's disease from a genome-wide association study of putative functional 
variants. Hum Mol Genet. Apr 15;16(8):865-73. 
Gyungah J et al. (2010) Meta-analysis confirms CR1, CLU and PICALM as Alzheimer 
disease risk loci and reveals interactions with APOE genotype. Arch Neurol. 
Dec;67(12):1473-84.  
Harold D et al. (2009) Genome-wide association study identifies variants at CLU and 
PICALM associated with Alzheimer's disease. Nat Genet. Oct; 41(10): 1088-93.  
Hayden EC. (2008) Alzheimer’s tests under fire. Nature; 455:1155. 
Heinzen EL Need AC, Hayden KM, et al. (2010) Genome-wide scan of copy number 
variation in late-onset Alzheimer's disease. J Alzheimers Dis. 19(1):69-77. 
Lee JH, Cheng R, Barral S (2011) Identification of Novel Loci for Alzheimer Disease and 
Replication of CLU, PICALM, and BIN1 in Caribbean Hispanic Individuals. Arch 
Neurol.  Mar;68(3):320-8. 
Jack CR, Knowpman DS, Jagust WJ, et al. (2010) Hypothetical model of dynamic biomarkers 
of the Alzheimer’s pathological cascade. Lancet Neurol 9:119-28. 
Jack CR, Peterson RC, Xu XC, et al. (1999) Prediction of AD with MRI-based hippocampal 
volume in mild cognitive impairment. Neurology; 52:1397-1403. 
Janssens ACJW, Ioannidis JPA, van Duijin CM, et al. (2011) Strengthening the Reporting of 
Genetic Risk Prediction Studies: The GRIPS Statement. Ann Intern Med; 154:421-5. 
www.intechopen.com
 The Clinical Spectrum of Alzheimer’s Disease  
– The Charge Toward Comprehensive Diagnostic and Therapeutic Strategies 
 
38
Kaddurah-Daouk R, Krishnan KR. (2009) Metabolomics: a global biochemical approach to 
the study of central nervous system diseases. Neuropsychopharmacology.  Jan; 
34(1):173-86. 
Kaddurah-Daouk R, Rozen S, Matson W, et al. (2010) Metabolomic Changes in 
autopsyconfirmed Alzheimer’s Disease. Alzheimers Dement. Nov 12. 
Kaufer D, Gandy S.(2009) APOE e4 and bapineuzumab: infusing pharmacogenomics into 
Alzheimer disease therapeutics. Neurology; 73:2052-3. 
Kauwe JSK, Cruchaga C, Karch CM, et al. (2011) Fine Mapping of Genetic Variations in 
BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal fluid biomarkers 
for Alzheimer’s disease. PLoS One. Feb 9;6(2):e15918.  
Kazee AM, Eskin TA, Laphan LW, et al. (1993) Clinicopathological correlates in Alzheimer 
disease: assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis 
Assoc Disord, 7:152-64. 
Killiany RJ, Gomez-Isla T, Moss M, et al. (2000) Use of structural magnetic resonance 
imaging to predict who will get Alzheimer’s disease. Ann Neurol; 47: 430-439. 
Killiany RJ, Hyman BT, Gomez-Isla T, et al. (2002) MRI measures of entorhinal cortex vs 
hippocampus in preclinical AD. Neurology; 58:1188-96. 
Korf ESC, Wahlund L-O, Visser PJ, et al. (2004) Medial Temporal Lobe Atrophy on MRI 
predicts dementia in patients with mild cognitive impairment. Neurology, 63:94-100. 
Kupfer DJ, Regier DA. (2010) Why All of Medicine Should Care about DSM-5. JAMA; 
303(19):1974-5. 
Lambert JC, Heath S, Even G. (2009) Genome-wide association study identifies variants at 
CLU and CR1associated with Alzheimer’s disease.  Nat Genet. Oct; 41(10):1094-9. 
Epub 2009 Sep 6. 
Lee JH, Cheng R, Barral S et al. (2010) Identification of Novel Loci for Alzheimer Disease 
and Replication of CLU, PICALM, and BIN1 in Caribbean Hispanic Individuals. 
Arch Neurol. 2011 Mar; 68(3):320-8. Epub Nov 8. 
Li H, Wetten S, Li L, et al. (2008) Candidate single-nucleotide polymorphisms from a 
genome wide association study of Alzheimer disease. Arch neurol; 65:45-53. 
Liang WS, Chen K, Lee W, et al. (2011) Association between GAB2 haplotype and higher 
glucose metabolism in Alzheimer’s disease-affected brain regions in cognitively 
normal APOEe4 carriers. Neuroimage. Feb 1;54(3):1896-902. Epub (2010) Oct 1 
Liang WS, Dunckley T, Beach TG, et al. (2008) Altered neuronal gene expression in brain 
regions differentially affected by Alzheimer’s diseases: a reference data set. Physiol 
Genomics 33 240-256. 
Lim A, Tsuang D, Kukull W et al. (1999) Clinico-pathological correlation of Alzheimer’s 
disease in a community-based case series. J Am Geriatr Soc; 47:564-69. 
Lovestone S, Francis P, Strandgaard K. (2007) Biomarkers for disease modification trials - the 
innovative medicines initiative and Add NeuroMed. J Nutr Health Aging; 11; 359-
61.  
Maes OC, Xu S, Yu B, et al. (2007) Transcriptional profiling of Alzheimer blood mononuclear 
cells by microarray. Neurobiol Aging, 28:1795-1809. 
Maes OC, Xu S, Yu B, et al. (2008) Transcriptional profiling of Alzheimer blood mononuclear 
cells by microarray. Neurobiology of Aging, 28 1795-1809. 
www.intechopen.com
 
Alzheimer’s Disease Genomics and Clinical Applications 
 
39 
Martins IJ, Hone E, Foster JK, et al. (2006) Apolipoprotein E, cholesterol metabolism, 
diabetes and the convergence of risk factors for Alzheimer’s disease and 
cardiovascular disease. Molecular Psy; 11:721-36. 
Mastroeni D, Grover A, Delvaux E, et al. (2010) Epigenetic Changes in Alzheimer’s disease: 
Decrements in DNA Methylation Neurobiol Aging 31(12): 2025-2037. 
McKhann G, Drachmann DA, Folstein M, e al. (1984) Clinical diagnosis of Alzheimer’s 
disease – report o the NINCDS-ADRDA workgroup under the auspices of 
Department of Health and Human Services Task Force on Alzheimer’s disease. 
Neurology; 34:939-44. 
Minagawa H, Watanabe AM, Akatsu H, et al. (2010) Homocysteine, Another Risk Factor for 
Alzheimer Disease, Impairs Apolipoprotein E3 function. J Biol Chem; 285(49):38382-
88. 
Morris JC, Roe CM, Xiong C, et al. (2010) APOE predicts amyloid-beta but not tau 
Alzheimer pathology in cognitively normal aging. Ann Neurol; 67:122-131. 
Morris JC, Storandt M, Miller JP, et al. (2001) Mild cognitive impairment represents early 
stage Alzheimer’s disease. Arch Neurol; 58:397-405. 
Mosconi L, Brys M, Switalski R, et al. (2007) Maternal family history of Alzheimer’s disease 
predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci U S A. 2007 
Nov 27;104(48):19067-72. Epub, Nov 14.19.  
Lin MT, Beal MF. (2006) Alzheimer's APP mangles mitochondria. Nat Med. Nov;12(11):1241-
3. 
Mosconi L, De Santi S, Brys M, et al. (2008) Hypometabolism and altered cerebrospinal fluid 
markers in normal Apolipoprotein E e4 carriers with subjective memory 
complaints. Biol Psy; 63(3): 609-18. 
Mueller SG, Weiner MW, Thal LJ, et al. (2005) Ways towards an early diagnosis in 
Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI). 
Alzherimers Dement; 1:55-66. 
Murrell A, Rakyan VK, Beck S. (2005) From genome to epigenome. Hum Mol Genet. Apr 
15;14 Spec No 1:R3-R10. Review. 
Naj AC, Beecham GW, Martin ER, et al. (2010) Dementia Revealed: Novel Chromosome 6 
Locus for Late-Onset Alzheimer Disease Provides Genetic Evidence for Folate-
Pathway Abnormalities. PLoS Genet. Sep 23;6(9). 58.  
Shulman JM, Chibnik LB, Aubin C, et al. (2010) Intermediate phenotypes identify Divergent 
Pathways to Alzheimer’s disease. PLoS One. Jun 21;5(6):e11244. 
Okonkwo OC, Alosco ML, Jerskey BA, et al. (2010) Cerebral atrophy, apolipoprotein E e4, 
and rate of decline in everyday function among patients with amnestic mild 
cognitive impairment. Alz Dement; 6:404-411. 
Panizzon M, Hauger R, Dale Am, et al. (2010) Testosterone modifies the effect of APOE 
genotype on hippocampal volume in middle-aged men. Neurology; 75:874-880. 
Pankratz VS, Dickson DW et al. (2010) Replication of CLU, CR1, and PICALM associations 
with alzheimer disease. Arch Neurol. Aug;67(8):961-4. 
Papassotiropoulos A, Fountoulakis M, Dunckley T, et al. (2006) Genetics, transcriptomics 
and proteomics of Alzheimer’s disease. J Clin Psychiatry 67(4): 652-670. 
www.intechopen.com
 The Clinical Spectrum of Alzheimer’s Disease  
– The Charge Toward Comprehensive Diagnostic and Therapeutic Strategies 
 
40
Peila R, White LR, Petrovich H, et al. (2001) Joint effect of the APOE gene and midlife 
systolic hypertension on late-life cognitive impairment: The Honolulu-Asia Aging 
Study. Stroke, 32:2882-2889. 
Petersen RC, Thomas RG, Grundman et al. (2005) Vitamin E and donepezil for the treatment 
of mild cognitive impairment. N Engl J Med, 352:2379-88. 
Petersen RC, Thomas RG, Grundman M, et al. (2005) Vitamin E and donepezil for the 
treatment of mild cognitive impairment. N Engl J Med, 352: 2379-88. 
Peterson RC. (2004) Mild cognitive impairment as a diagnostic entity. J Int Med, 256:183–94. 
Petrovich H, White LR, Ross GW, et al. (2001) Accuracy of clinical criteria for AD in the 
Honolulu-Asia Aging Study: a population-based study. Neurology, 57:226-34. 
Poduslo SE, Huang R, Huang J et al. (2009) Genome screen of late-onset Alzheimer’s 
extended pedigrees identified TRPC4AP by haplotype analysis. Am J Med Genet B 
Neuropsychiatr Genet, 150B:50-5. 
Portelius E, Zetterberg H, Gobom J, et al. (2008) Targeted proteomics in Alzheimer’s disease: 
Focus on amyloid-beta. Expert Rev Proteomics 5(2): 225-37. 
Price JL, Morris JC. (1999) Tangles and plaques in nondemented aging and preclinical 
Alzheimer disease. Ann Neurol, 45:358-68. 
Prince JA, Feuk L, Gu HF, et al. (2003) Genetic variation in a haplotype block spanning IDE 
influence Alzheimer’s disease.  Hum Mutat, 22: 363-71. 
Reiman EM, Webster JA, Myers AJ, et al. (2007) GAB2 alleles modify Alzheimer’s risk in 
APOE episilon4 carriers. Neuron, 54:713-20. 
Ringman JM, Medina LD, Braskie M, et al. (2011) Effects of Risk Genes on BOLD activation 
in presymptomatic carriers of familial Alzheimer’s disease mutations during a 
novelty encoding task. Cerebral Cortex. Apr;21(4):877-83. 
Risner ME, Saunders AM, Altman JF, et al. (2006) Efficacy of rosiglitazone in a genetically 
defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics 
J, 6 :246-54. 
Ritchie K, Lovestone S. (2002) The dementias. Lancet. Nov 30; 360 (9347):1759-66. 
Rogaeva E, Meng Y, Lee JH, et al. (2007) The neuronal sortilin-related receptor SORL1 is 
genetically associated with  Alzheimer’s disease. Nat Genet. Feb; 39(2): 168-77. 
Roses AD, Lutz MW, Amrine-Madsen H, et al. (2009) A TOMM40 variable-length 
polymorphism predicts age of late-onset Alzheimer’s disease. Pharmacogenomics, 
69:1-10. 
Roses AD. (1996) Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev 
Med. 47:387-400. Review. 
Rusanen M, Rovio S, Gan Du T, et al. (2010) Midlife smoking, apolipoprotein E and risk of 
dementia and Alzhiemer’s disease: A population-based cardiovascular risk factors, 
aging and dementia study. Dement Geriatr Disord, 30:277-284. 
Rye PD, Booij BB, Grave G, et al. (2010) A novel blood test for the early detection of 
Alzheimer’s Disease. J Alzheimer’s Disease, 23:1-9. 
Santoro A, Balbi V, Balducci E, et al. (2010) Evidence for Sub-haplogroup h5 of 
Mitochondrial DNA as a Risk Factor for Late Onset Alzheimer’s Disease. PLoS One, 
Aug 6;5(8):e12037.  
Serretti A, Olgiati P, Ronchi DD. (2007) Genetics of Alzheimer’s disease: A rapidly evolving 
field. Journal of Alzheimer’s disease, 73-92. 
www.intechopen.com
 
Alzheimer’s Disease Genomics and Clinical Applications 
 
41 
Seshadri S et al. (2010) Genome-wide analysis of genetic loci associated with Alzheimer 
disease. JAMA, May 12; 303(18):1832-40. 
Shen L, Kim S, Risacher SL, et al. (2010) Alzheimer's Disease Neuroimaging Initiative. 
Whole genome association study of brain-wide imaging phenotypes for identifying 
quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage, 
53(3):1051-63. 
Simonsen AH, McGuire J, Hansson O, et al. (2007) Novel Panel of Cerebrospinal Fluid 
Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients 
With Mild Cognitive Impairment. Arch Neurol, 64(3):366-370. 
Slifer MA, Martin ER, Gilbert JR, et al. (2009) Resolving the relationship between 
Apolipoprotein E and depression. Neurosci Lett, 455(2): 116-119.   
Stamatoyannopoulos JA, Dunham I. (2008) Epigenomics at the tipping point. 
Pharmacogenomics, 9:12, 1781-83. 
Stein JL, Hua X, Morra JH et al. (2010) Genome-wide Analysis reveals novel genes 
influencing temporal lobe structure with relevance to neurodegeneration in 
Alzheimer’s disease. Neuroimage, 51(2): 542-44. 
Sultana R, Boyd-Kimball D, Cai J, et al. (2007) Proteomics Analysis of the Alzheimer’s 
Disease Hippocampal Proteome. JAD, 11(2): 153-164. 
Tan MG, Chua WT, Esiri MM, et al. (2010) Genome wide profiling of altered gene 
expression in the neocortex of AD. J Neuroscience Research, 88:1157-1169. 
Tang Y, Lu A, Arnow BJ, et al. (2001)Blood genomic responses differ after stroke, seizures, 
hypoglycemia and hypoxia: blood genomic fingerprints of disease. Ann. Neurol., 50: 
699 – 707. 
Tang Y, Nee AC, Lu A, et al. (2003) Blood genomic expression profile for neuronal injury. J. 
Cereb. Blood Flow Metab. 23: 310 – 319. 
Tanzi RE, Dovacs DM, Kim TW, et al. (1996) The gene defects responsible for familial 
Alzheimer’s disease. Neurobiol Dis 3:159-168. 
Tanzi RE. (1999) A genetic dichotomy model for the inheritance of Alzheimer’s disease and 
common age-related disorder. J Clin Invest, 104:1175-1179. 
Trachtenberg AJ, Filippini N, Mackay CE. (2010) The effects of APOE-epsilon4 on the BOLD 
response. Neurobiol Aging. Apr 19.  
Tsuang MT, Nossova N, Yager T, et al. (2005) Assessing the validity of blood-based gene 
expression profiles for the classification of schizophrenia and bipolar disorder: a 
preliminary report. Am. J. Med. Genetics Part B;  133B: 1 - 5. 
Varma AR, Snowden JS, Lloyd JJ, et al. (1999) Evaluation of the NINCDS-ADRD criteria in 
the differentiation of Alzheimer’s disease and frontotemporal dementia. J Neurol 
Neurosurg Psychiatry; 66:184-88. 
Vemuri P, Wiste HJ, Weigand SD, et al. (2010) Effect of Apolipoprotein E on biomarkers of 
Amyloid Load and Neuronal Pathology in Alzheimer disease. Ann Neurol,  67:308-
16. 
Wang P, Hong C, Lin K et al. (2011) APOEe4 increases risk of progression from amnestic 
mild cognitive impairment to Alzheimer’s disease among ethnic Chinese in 
Taiwan. J Neurol Neurosurg Psychiatri, 82:165-9. 
Wang S, Oelze B, Schumacher A. (2008) Age-specific epigenetic drift in late-onset 
Alzheimer’s disease. PLoS ONE, Jul 16:3(7): e2698.   
www.intechopen.com
 The Clinical Spectrum of Alzheimer’s Disease  
– The Charge Toward Comprehensive Diagnostic and Therapeutic Strategies 
 
42
Webster JA, Myers AJ, Pearson JV, et al. (2008) Sorl1 as an Alzheimer's disease 
predisposition gene? Neurodegener Dis; 5(2):60-4.  
Wimo A, Winbald B, Aguero Torres H, et al. (2003) The magnitude of dementia 
occurrencein the world. Alz Dis Assoc Disord, 17: 63-67. 
Wu J, Basha MR, Zawia NH. (2008) The environment, epigenetics and amyloidogenesis. J 
Mol Neurosci, 34(1): 1-7. 
Yip AG, McKee A, Green RC, et al. (2005) APOE, vascular pathology and the AD brain. 
Neurology, 65:259-265. 
Zellner M, Veitinger M, Umlauf E. (2009) The Role of Proteomics in Dementia and 
Alzheimer’s Disease. Acta Neuropathol, 118: 181-195. 
www.intechopen.com
The Clinical Spectrum of Alzheimer's Disease -The Charge Toward
Comprehensive Diagnostic and Therapeutic Strategies
Edited by Dr. Suzanne De La Monte
ISBN 978-953-307-993-6
Hard cover, 362 pages
Publisher InTech
Published online 06, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The Clinical Spectrum of Alzheimer's Disease: The Charge Toward Comprehensive Diagnostic and
Therapeutic Strategies is highly informative and current. Acknowledged experts in the field critically review
both standard and under-appreciated clinical, behavioral, epidemiological, genetic, and neuroimaging
attributes of Alzheimer's disease. The collection covers diverse topics of interest to clinicians and researchers
alike. Experienced professionals and newcomers to the field will benefit from the read. The strengths and
weaknesses of current clinical, non-invasive, neuro-imaging, and biomarker diagnostic approaches are
explained. The perspectives give fresh insights into the process of neurodegeneration. Readers will be
enlightened by the evidence that the neural circuits damaged by neurodegeneration are much broader than
conventionally taught, suggesting that Alzheimer's could be detected at earlier stages of disease by utilizing
multi-pronged diagnostic approaches. This book inspires renewed hope that more effective treatments could
be developed based upon the expanding list of potential therapeutic targets.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Tih-Shih Lee and Mei Sian Chong (2011). Alzheimer’s Disease Genomics and Clinical Applications, The
Clinical Spectrum of Alzheimer's Disease -The Charge Toward Comprehensive Diagnostic and Therapeutic
Strategies, Dr. Suzanne De La Monte (Ed.), ISBN: 978-953-307-993-6, InTech, Available from:
http://www.intechopen.com/books/the-clinical-spectrum-of-alzheimer-s-disease-the-charge-toward-
comprehensive-diagnostic-and-therapeutic-strategies/alzheimer-s-disease-genomics-and-clinical-applications
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
